iBio Names Elizabeth Stoner to Board, Adds Biotech R&D Leader to Compensation Committee
iBio appointed Dr. Elizabeth Stoner as an independent director and Compensation Committee member, replacing Eef Schimmelpennink who stepped down. Stoner brings over 35 years of global R&D leadership at Merck, Semma Therapeutics and Rhythm Pharmaceuticals as iBio prepares for its first human clinical trial.
1. Board Appointment Details
iBio has appointed Dr. Elizabeth Stoner as an independent member of its Board of Directors and as a member of the Compensation Committee. She replaces Eef Schimmelpennink, who stepped down, marking a governance shift as the company moves toward clinical-stage operations.
2. Professional Background
Dr. Stoner has more than 35 years of experience leading global research and development, including senior roles at Merck Research Laboratories, interim CEO at Semma Therapeutics, and founder and CMO at Rhythm Pharmaceuticals. She currently partners with MPM BioImpact to guide clinical strategy and serves on multiple biotech boards.
3. Strategic Implications
This board addition arrives as iBio embarks on its first human clinical trial for IBIO-610 and IBIO-600 programs. Stoner’s regulatory, clinical execution and investment-industry expertise is expected to support the advancement of AI-driven cardiometabolic and cardiopulmonary therapies.